Sensars is a technology company.
Sensars has raised $30K across 1 funding round.
Sensars has raised $30K in total across 1 funding round.
Sensars has raised $30K in total across 1 funding round.
Sensars's investors include Health Wildcatters.
Sensars is a Swiss medtech startup developing neuromodulation technologies, primarily the SENSY implantable system, to restore sensory feedback in extremities and treat chronic peripheral neuropathic pain.[1][2][3] It targets patients with diabetic neuropathy, amputees, and others suffering from nerve damage, addressing the core issue of disrupted sensory loops that current treatments fail to fix, such as preventing diabetic foot complications through closed-loop stimulation via wearable sensors and intraneural electrodes.[3][5] With under 25 employees and less than $5 million in revenue and funding (including a €1.1 million round in 2024), Sensars has gained FDA Breakthrough Device Designation and partnerships with top institutions, positioning it for clinical advancement.[1][3][4]
Sensars Neuroprosthetics Sarl was co-founded by Francesco Petrini, Stanisa Raspopovic, and Silvestro Micera, neuroengineering experts with over 30 years combined in nerve interfacing, including pioneering Europe's first implants for sensory feedback in amputees and pain treatment—results featured on Nature and Science covers.[2] The idea emerged from their research securing over €10 million in grants (including €2.5 million for Sensars), inventing an implantable stimulator that penetrates peripheral nerves for selective fiber access, unlike traditional cuff electrodes.[2][3] Early traction included FDA Breakthrough Designation for SENSY and awards like Business Worldwide's Top 20 Most Innovative Companies (2022), with key hires like COO Guy Siman (20+ years in medtech, multiple CE marks), CSO Dan Merrill (ex-Alfred Mann Foundation Fellow), and QA/RA Manager Magdalena Czarnievicz (10+ years in class III devices).[2][4][6]
Sensars stands out in neuromodulation through:
Sensars rides the neuromodulation boom, fueled by aging populations and rising diabetes (millions affected globally by neuropathy), where no therapies restore sensation—only mask symptoms.[1][3][5] Timing aligns with neurotech advances in precise implants (post-Neuralink hype) and closed-loop AI-driven devices, amplified by post-2020 medtech funding resurgence and FDA fast-tracks for breakthroughs.[3][4] Market tailwinds include chronic pain's $100B+ burden and demand for non-opioid solutions; Sensars influences by pioneering peripheral (vs. brain) stimulation, enabling scalable prosthetics and preventive care, potentially reshaping diabetes management and expanding to metabolic disorders.[2][3][4]
Sensars is poised for clinical trials and commercialization of SENSY post-€1.1M funding, targeting 2025+ FDA approvals and EU CE marking, with expansion to obesity/depression via peripheral pathways.[1][3][6] Trends like AI-optimized stimulation and global diabetes surge (projected 700M+ cases by 2045) will accelerate adoption, evolving Sensars from neuropathy pioneer to neuromodulation platform leader—restoring not just sensation, but lives long underserved by medtech.[2][3][4] This positions it to capture a slice of the growing $10B+ neurostimulation market, building on its innovative edge.
Sensars has raised $30K across 1 funding round. Most recently, it raised $30K Seed in September 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2024 | $30K Seed | Health Wildcatters |